Table of Contents
<< Previous Issue | Apr 2023 (Vol: 2023, Issue: 4) | Next Issue >> |
- Section: Licensing
-
BioNTech Enters ADC Field with US$1.6 B+ DualityBio Licensing Deal
-
Bristol Myers Squibb Signs US$1 B+ Deal with Tubulis for Solid Tumour ADCs
- Section: Opinion & Analysis
-
M&A Activity Starts to Pick up in Q2 2023
- Section: Research & Development
-
Novartis Signs US$1.7 B Deal with Bicycle Therapeutics for Cancer Radiopharmaceuticals